Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Sciences Launches Five-Year WHO Partnership to Accelerate Elimination of Visceral Leishmaniasis in High-Burden Regions

Fineline Cube May 22, 2026
Company Deals

Johnson & Johnson Partners with Abu Dhabi DOH to Launch Global Surgical Intelligence Network Powered by Polyphonic Platform

Fineline Cube May 22, 2026
Company Deals

Eli Lilly Acquires Engage Biologics for $202M to Bolster Genetic Medicines Portfolio with Tethosome Platform

Fineline Cube May 22, 2026
Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area

Fineline Cube May 23, 2026
Company Drug

Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib

Fineline Cube May 23, 2026
Company Deals

Sumitomo Pharma Secures Rights to Vibegron for Asian Markets

Fineline Cube Mar 8, 2023

Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical...

Company Deals

Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies

Fineline Cube Mar 8, 2023

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company Deals

Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment

Fineline Cube Mar 8, 2023

China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai...

Company Deals

F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS

Fineline Cube Mar 8, 2023

UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from...

Company Drug

Biocytogen’s YH008 Gets NMPA Approval for Phase I Study

Fineline Cube Mar 8, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...

Company Deals

Heranova Closes $10M Seed Round for Women’s Health Solutions

Fineline Cube Mar 8, 2023

Heranova Lifesciences Holding, a provider of women’s health solutions, has announced the successful closure of...

Company Drug

Inmagene’s Tavalisse First Prescribed in China for ITP Treatment

Fineline Cube Mar 8, 2023

China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...

Company Drug

AusperBio Initiates Phase I Trial for AHB-137 in New Zealand

Fineline Cube Mar 8, 2023

Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...

Policy / Regulatory

China’s Party and State Institutions Reshuffle: Key Changes for Healthcare and Finance

Fineline Cube Mar 8, 2023

The second plenary session of the 20th Communist Party of China (CPC) Central Committee has...

Company Drug

BrightGene’s Generic Halaven Approved for Marketing in China

Fineline Cube Mar 7, 2023

China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National...

Company Deals

Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis

Fineline Cube Mar 7, 2023

UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd,...

Company Drug

Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine

Fineline Cube Mar 7, 2023

US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from...

Policy / Regulatory

Sunshine Medical Procurement Platform Announces VBP Tender Results for Yangtze River Delta

Fineline Cube Mar 7, 2023

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare...

Company Deals

Neo Modulus Secures Series B Funding for Regenerative Medical Device Development

Fineline Cube Mar 7, 2023

Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised...

Company Drug

Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions

Fineline Cube Mar 7, 2023

Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...

Policy / Regulatory R&D

Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies

Fineline Cube Mar 7, 2023

Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...

Company Drug

Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial

Fineline Cube Mar 7, 2023

Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...

Company Policy / Regulatory

BGI Group Subsidiaries Added to US Trade Blacklist by Commerce Department

Fineline Cube Mar 7, 2023

The US Department of Commerce (DOC)’s Bureau of Industry and Security (BIS) has added 37...

Company

Sanyou Biopharmaceuticals Expands Global Reach with New Cambridge Office

Fineline Cube Mar 6, 2023

Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new...

Company Drug

Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment

Fineline Cube Mar 6, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status...

Posts pagination

1 … 558 559 560 … 670

Recent updates

  • Zai Lab Announces Executive Leadership Reshuffle as COO Josh Smiley Steps Down After Nearly Four Years
  • Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area
  • Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib
  • Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment
  • Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Zai Lab Announces Executive Leadership Reshuffle as COO Josh Smiley Steps Down After Nearly Four Years

Company Drug

Allergan Aesthetics Secures CHMP Positive Opinion for Boey (TrenibotulinumtoxinE) in Glabellar Lines Treatment Across European Economic Area

Company Drug

Lupeng Pharma Enrolls First Patient in Global Phase 3 ROCKET-CLL Trial of Fourth-Gen BTK Inhibitor Rocbrutinib vs. Pirtobrutinib

Company Drug

Eli Lilly’s Retatrutide Delivers Breakthrough Weight Loss Results in Phase 3 TRIUMPH-1 Trial for Obesity Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.